Michael Matte Named CFO at Aspen Group, Inc. (ASPU)

Posted on 5/17/2013 @ 10:10 AM in #Stocks by QualityStocks 0 comments

Yesterday, Aspen Group, a nationally accredited online postsecondary education company, announced that Michael Matte has been named as the company’s Chief Financial Officer, effective immediately. Matte is taking over this role form David Garrity, Aspen’s former CFO; Garrity has been appointed EVP, Corporate Development, where he will head Aspen’s investor relations activities, M&A, and corporate partnerships. He will also be responsible for building Aspen’s corporate sales function, which is focused on institutional partnerships. Matte is joining Aspen Group having most recently been at MeetMe, Inc. as its CFO. He has over 20 years of experience as a CFO of both technology and public companies. A Certified Public Accountant in Florida, Matte began his career in public accounting with Price Waterhouse. He holds a Bachelors of Science from Florida State University, Michael Mathews, Aspen’s Chairman and CEO, remarked, “We are delighted to have attracted Mike to join the Aspen team and we welcome him. He is

Dynamics Research Corp. (DRCO) Announces Extension of Veterans Relationship Management Contract

Posted on 5/17/2013 @ 10:09 AM in #Stocks by QualityStocks 0 comments

Leading technology and management consulting company Dynamics Research Corp. (DRC) has announced that the Department of Veterans Affairs (VA), through the General Services Administration, has exercised the third year option of the Veterans Relationship Management Portfolio Monitoring and Coordination contract, extending the period of performance until May 10, 2014. The contract was awarded in May 2010 to High Performance Technologies, Inc., the company’s wholly owned subsidiary, and has a five-year performance period through May 2015 and a total contract value of $125.5 million. A multi-year initiative, Veterans Relationship Management restarts previously troubled programs with the end goal of providing veterans, service members, and eligible beneficiaries with fast, accurate, and easily accessible healthcare information and benefits. DRC delivers the next generation of IT solutions geared for veterans, providing a full range of program and portfolio management services across more than 30 projects. The

eFuture Information Technology, Inc. (EFUT) to Provide Cloud Servers to SCA China

Posted on 5/17/2013 @ 10:09 AM in #Stocks by QualityStocks 0 comments

On May 16, eFuture Information Technology announced that it would be providing SCA China Holding Co. with cloud services, in the form of its Data Link products. eFuture’s cloud services launched in May of 2012, and is available with no added hardware via a monthly subscription fee. eFuture is focused on providing software and services to China’s retail and consumer goods industries, as well as providing software and services to manufacturers, distributors, wholesalers, logistics companies, and retailers in China’s front-end supply chain market. The company’s products include Salesforce Automation, a sales management application allowing manufacturers and their distributors to manage sales force efficiency. Data Link products, such as the products specified in the SCA agreement, are distributor relationship management applications that allow manufacturers and distributors to access supply chain data. eFuture’s Data Link services will allow SCA to access real-time sales, inventory, and replenishment

Liberator Medical Holdings, Inc. (LBMH) Posts Year-over-Year Improvements in Q2, FH2013

Posted on 5/17/2013 @ 10:08 AM in #Stocks by QualityStocks 0 comments

Liberator Medical Holdings reported its financial results for the second fiscal quarter and six months ended March 31, 2013, reflecting revenue and earnings growth for both periods. Sales for second quarter of 2013 increased 14.1 percent to $16.7 million, as compared with sales of $14.6 million for the same three months of 2012. Sales for the six months ended March 31, 2013, increased by 16.4 percent to $34.2 million, as compared with sales of $29.4 million for the six months ended March 31, 2012. Net income was $1.4 million, or $0.03 diluted earnings per share, compared with net income of $0.7 million, or $0.01 per share, for the second quarter last year. For the first six months of 2013, net income was $2.7 million, or $0.05 per share, compared to $1.1 million, or $0.02 per share, reported for the first six months of 2012. Second-quarter income from operations increased 107.2 percent to $2.3 million, as compared to $1.1 million in the prior year period. For the first six months of 2013, income from

Industry Veteran Clive Raines Joins iTalk, Inc. (TALK) as Director of Australasia and Europe Operations

Posted on 5/16/2013 @ 5:19 PM in #Stocks by QualityStocks 0 comments

A global provider of advanced communications and mobile broadband services, iTalk has announced the appointment of Clive Raines as Director of Australasia and Europe Operations. With high voice quality and the lowest prices, iTalk Mobile is currently pushing the market for an industry alternative to traditional cellular coverage. Raines, whose resume includes extensive experience in better business practices in Australasia and Europe, will be welcomed to the team for his strong background in sales, marketing, strategic product development, and distribution. David F. Levy, Chief Executive Officer of iTalk, commented, “The Australasia and Europe region is poised for the same explosive growth in new communication devices and services that iTalk is currently offering to the US marketplace.” Continuing on Levy stated, “Clive is an excellent addition to our growing team and his 25 years of international communications, product development and distribution experience in Australasia and European countries, will

DoMark International, Inc. (DOMK) Targets Smart Market

Posted on 5/16/2013 @ 5:18 PM in #Stocks by QualityStocks 0 comments

Mobile devices have become an indispensable personalized link to the outside world in ways that the developers of the original location-locked telephone never could have imagined. Increasingly we take our world with us, demanding answers and reach wherever we are, at any time of the day or night. It’s a tall order when you consider the volume and complexity of every person’s unique information flow. Over half of online activity now occurs through mobile devices, especially impressive when you consider the fact that Google alone, a focal point for online activity, gets over a billion visits every day. It translates into billions of mobile devices serving the human global population, and a market of staggering size and scope led by Samsung, Nokia, and Apple. Although every new iteration of mobile device brings with it new capabilities and perceptions, which can cause swings in the mobile marketplace, the companies that provide accessories to such devices are in a smart position. Changes in devices are often

Northwest Biotherapeutics, Inc. (NWBO) Begins Phase III Trial of DCVax-L for Brain Cancer

Posted on 5/16/2013 @ 1:11 PM in #Stocks by QualityStocks 0 comments

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products for the American and European markets to treat cancers more effectively than current treatments, while costing less, and without the toxicities associated chemotherapies. It is currently working on the DCVax-L personalized immune therapies for solid tumor cancers. The company announced today that its Phase III clinical trial with DCVax-L for brain cancer has begun at King’s College Hospital in the U.K., a major European center for neuro-oncology. Other sites across Europe, including three more in the U.K. and nearly 20 in Germany, are in varying stages of preparations for the trial. This particular Phase III trial is for newly diagnosed Glioblastoma multiforme (GBM). This is the most common and lethal form of brain cancer. The trial is well under in the United States with 46 active sites presently. Total enrollment in the U.S. and Europe is expected to reach 312 patients. Under present treatment methods, brain

Rafarma Pharmaceuticals, Inc. (RAFA) Continues to Build Drug Pipeline

Posted on 5/16/2013 @ 1:10 PM in #Stocks by QualityStocks 0 comments

Rafarma Pharmaceuticals is one of Russia’s newest and most promising pharmaceutical companies. A company whose development and growth is being actively encouraged by the government, in a move to lessen Russian dependence upon western pharmaceutical companies for widely used pharmaceuticals, Rafarma is currently specializing in the production of generic antibiotics, but has a growing pipeline of other drugs, including proprietary products already approved. The company expects significant near-term results with its line of current and researched pharmaceuticals, including the following group of antibiotics. • Benzalconium Fluoride – Open randomized study of the efficacy and safety of the drug “benzalkonium fluoride, topical solution 1 %” in patients with purulent-infected wounds.• Benzomet – Open randomized study of the efficacy and safety of the drug “benzomet, vaginal suppositories” in patients with urogenital trichomoniasis.• Benzolete – Open randomized study of the efficacy and safety of “benzolete,

Trio Resources, Inc. (TRII) Reports Q2 2013 Financial Results, Achieves First Revenues

Posted on 5/16/2013 @ 10:14 AM in #Stocks by QualityStocks 0 comments

Trio Resources, an exploration and small-scale processing company reported financial results for the second quarter ended March 31, 2013, marking the first revenues recorded since the company’s inception in May, 2012. The company also recapped its first-quarter achievements, including its five-year off-take agreement with United Commodity AG. “During the first quarter, we continued to distinguish ourselves from other junior mining companies by executing on our strategy to monetize our significant stockpiles of mineralized materials and securing a five year off-take agreement with United Commodity AG, one of the world’s leading processors of precious metals,” Duncan Reid, CEO of Trio Resources stated in the press release. “By closing the more than $30 million United Commodity deal, we not only reached a major milestone by generating our first revenues as a public company, but we secured a consistent and significant revenue stream that will enable us to fund operations and future growth opportunities for years

eMagin Corp. (EMAN) to Introduce World’s Brightest Full Color OLED Microdisplays

Posted on 5/16/2013 @ 10:14 AM in #Stocks by QualityStocks 0 comments

eMargin, a leader in OLED microdisplay technology, OLED microdisplay manufacturing know-how, and mobile display systems, announced yesterday that it has developed the world’s brightest family of super bright, energy efficient, and full color organic light emitting diode (OLED) microdisplays, called the Color OLED-XLS™. At 1000 nits of luminance, the Color OLED-XLS™ blows away the industry standard for brightness four times over. This new display is fully compatible with eMargin’s entire VGA, SVGA, SXGA, and WUXGA, and only requires half of the power of the company’s current color displays at the same brightness. This breakthrough display technology enables a much broader range of optical solutions for augmented vision/reality products used in simulation and training devices, or any other head-mounted display application. Additionally, this technology is perfectly suited for medical, maintenance, and process-control “see-through” data glasses and safety goggles. eMagin’s initial showcase of its breakthrough

VistaGen Therapeutics, Inc. (VSTA) Continues to Move Forward with Revolutionary Drug Testing Technology

Posted on 5/15/2013 @ 5:14 PM in #Stocks by QualityStocks 0 comments

VistaGen is a biotech company focused on using stem cell technology to generate new, safer variants (drug rescue variants) of once-promising small molecule drug candidates that were developed but ultimately discontinued by large pharmaceutical companies due to heart or liver toxicity issues. VistaGen aims to use their proprietary stem cell technology as a previously unavailable cost effective way to re-examine and ultimately “rescue” such lost drugs, thereby recovering the value from what is usually a substantial prior investment in research and development. The company recognizes the drug discovery and development crisis facing the U.S. pharmaceutical industry, where increasingly big investments are required for new drug development but not enough new drugs are being finally approved. Using its technology to derive mature human heart and liver cells from pluripotent stem cells, VistaGen continues to develop unique bioassay systems for assessing potential toxicity issues right in the laboratory, providing a

Cinedigm Digital Cinema Corp. (CIDM) and Universal Studios Home Entertainment Announce Home Entertainment Distribution Deal

Posted on 5/15/2013 @ 1:56 PM in #Stocks by QualityStocks 0 comments

Cinedigm and Universal Studios Home Entertainment have announced a strategic multi-year agreement. Premier home entertainment company, Universal Studios will provide supply-chain services across the United States for Cinedigm’s growing library of digital films and other content. Cinedigm’s existing sales team will continue implementing sales directly to consumers. Cinedigm’s existing library holds over 5,000 titles of which includes acclaimed independent films, award-winning documentaries from Docurama Films®, next-gen indies from Flatiron Film Company®, as well as festival picks through partnerships with Tribeca Film and the Sundance Institute. Cinedigm also distributes award-winning and Oscar®-nominated films. Chris McGurk who currently sits as Chairman of the Board and as CEO of Cinedigm commented, “Having worked with Craig Kornblau at both Disney and Universal, I’m thrilled to be working with him and the entire Universal Studios Home Entertainment team again. With Universal by our side, we look forward

First Independence Corp. (FICF) Codesmart University™ ICD Courses Approved for CEU Credits by Top Medical Coding Associations

Posted on 5/15/2013 @ 1:56 PM in #Stocks by QualityStocks 0 comments

First Independence Corp. and its subsidiary, The Codesmart™ Group, an ICD-10 education and solutions group, reported that its Codesmart™ University study programs are now eligible for Continuing Education Units (CEU) for existing medical coders, as certified by the Association of Professional Coders (APPC) and the American Health Information Management Association (AHIMA). ICD-10, or the tenth revision of the International Classification of Diseases, is approved by the World Health Organization for the designation of the aspects of disease treatment that include categories of diseases and treatment modalities for them. This tenth revision of the ICD has been broken down into more than 141,000 designations vs. only 17,000 codes, diagnoses, and procedures in the previous version ICD. The Codesmart Group says the U.S. Department of Health and Human Services has mandated that all medical practices, hospitals, and other medical record keeping organization be trained and ICD-10 compliant by October 1, 2014.

Enrollment Completed for European Clinical Trial of Cardica, Inc. (CRDC) MicroCutter XCHANGE 30

Posted on 5/15/2013 @ 1:55 PM in #Stocks by QualityStocks 0 comments

Cardica announced the completion of enrollment for the European clinical study of its MicroCutter XCHANGE 30, which is a cartridge-based cutting/stapling device with a 5-millimeter shaft diameter and a cross-sectional area that is more than six times smaller than the standard 12-millimeter surgical staplers currently in use. The trial has been created to evaluate the XCHANGE 30’s safety in various gastrointestinal surgical procedures in support of a 510(k) filing for market clearance from the FDA. The company expects to file regulatory documents with the FDA in the third quarter of calendar 2013, based on consistent product performance and positive unaudited clinical outcomes of the trial so far. “We would like to express our sincere thanks to the investigators and patients for their enthusiasm in participating in the trial to advance the XCHANGE 30, the smallest cutting and stapling device available today,” said Cardica President and CEO Bernard A. Hausen, M.D., Ph.D. In total, 160 patients have been

Brekford Corp. (BFDI) Wins Contract with the City of Asheville, North Carolina

Posted on 5/15/2013 @ 1:54 PM in #Stocks by QualityStocks 0 comments

Brekford has been a public safety technology and services solutions partner to public sector agencies at the local, state, and federal level for over ten years. The company’s range of solutions include automated traffic enforcement programs, delinquent municipal receivables processing and collection, turnkey law enforcement vehicle upfitting services, and a suite of mobile computer and video technology products. The company announced today that it won a three-year contract with the city of Asheville, North Carolina, for the provision of parking citation issuance, processing, and delinquent collections. The contract includes the provision of wireless handheld enforcement devices, web-based parking citation processing software and other processing services, in-state and out-of-state DMV look-ups, notice printing and mailing, real-time public access website, online appeal system, payment processing, and optional delinquent collection services. Brekford will coordinate closely with Asheville’s Parking and

The Guitammer Company, Inc. (GTMM) Reports Q1 2013 Financial Results and Highlights

Posted on 5/15/2013 @ 1:54 PM in #Stocks by QualityStocks 0 comments

The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker®-brand low frequency audio transducers that provide an immersive entertainment experience for audiences, just announced its results for the first quarter ended March 31, 2013. The company featured the following financial highlights and recent developments: • Net loss decreased by 6% for the three months ended March 31, 2013 compared to the three months ended March 31, 2012.• Total current assets increased 5.9%, or $51,034, to approximately $912,000, as of March 31, 2013 compared to March 31, 2012, attributed primarily to the increase in cash which resulted from the sale of the Company’s stock and warrants in March 2013.• Net increase in cash and cash equivalents of $123,001, as of March 31, 2013 compared to March 31, 2012, primarily consisting of net cash provided by financing activities of $230,217 partially offset by net cash used in operating activities of $107,216.• For the three months ended March

Golden Cross Resources, Inc. (CNSX:GOX), Blue Gold Tailing Technologies Ltd. Focus on Innovative Water Purification Solutions

Posted on 5/15/2013 @ 1:53 PM in #Stocks by QualityStocks 0 comments

Blue Gold Tailing Technologies is a water remediation company focusing on transforming contaminated waters into pure, safe, drinkable water. The company’s environmentally safe solutions address global water purification, restoration, and contamination issues, adhering to EPA guidelines as to what constitutes safe agricultural or drinkable water. Blue Gold then tailors these guidelines to acceptable standards in the jurisdiction in which the technology is used. This technology can also be used to recover heavy and precious metals from mine tailings. Privately held Blue Gold is currently undergoing acquisition by Golden Cross Resources via merger with Golden Cross’ Ontario subsidiary. The emerging company will operate as “Blue Gold Water Technologies,” functioning as a waste water remediation and tailings processing business with three proprietary product lines: Pureinator Plants, Process Mine Tailings, and Smartsan. The company’s low-cost Pureinator Plants produce safe, potable water from any source,

International Stem Cell Corp. (ISCO) Scheduled to Present at Two Upcoming Investor Conferences

Posted on 5/15/2013 @ 10:45 AM in #Stocks by QualityStocks 0 comments

International Stem Cell Corporation, a biotechnology company developing novel stem cell based therapies, this morning told investors that it will be presenting at two investor conferences in May. Dr. Simon Craw, Executive Vice President, will present at the B. Riley & Co. 14th Annual Investor Conference in Santa Monica, CA, Monday May 20, 2013, and the Marcum LLP 2nd Annual MicroCap Conference in New York City, New York, on Thursday, May 30, 2013. Details: B. Riley & Co. 14th Annual Investor ConferenceDate: Monday, May 20, 2013Time: 7:30 p.m. Eastern Time / 4:30 p.m. Pacific TimeLocation: Loews Santa Monica Beach Hotel, Los Angeles, CA Marcum LLP 2nd Annual MicroCap ConferenceDate: Thursday, May 30, 2013Time: 3:00 p.m. Eastern Time / 12:00 p.m. Pacific TimeLocation: Grand Hyatt Hotel, New York, NY Those interested in attending the conferences or arranging a face-to-face meeting with ISCO’s management team should contact the conference organizers. To register for the event, please visit the conference

Loans4Less.com, Inc. (LFLS) Featured in Exclusive CEOCFO Magazine Interview

Posted on 5/15/2013 @ 10:44 AM in #Stocks by QualityStocks 0 comments

Loans4Less.com, an online mortgage loan brokerage firm, was recently interviewed by CEOCFO Magazine. Company CEO Steven M. Hershman discussed several key company and industry points pertinent to consumers and the investment community. Loans4Less.com’s unique foothold in the mortgage industry was discussed, as well as: • The allure of Loans4Less.com vs. a bank lender• How the Company was established• The proven strategy that ensured resilience through the financial crisis• The current mortgage environment in California• Nationwide expansion goals via strategic partnerships, mergers or licensing agreements• The value of highest quality, consistent customer service Recently ranked 66th out of 200 top residential mortgage loan originators in the United States, Loans4Less.com has positioned itself as a debt-free, fully sustainable small business seeking out select avenues to expand its market position. “We are not a company that has debt or cash flow problems, so we are offering a very clean perspective and

Cardium Therapeutics, Inc. (CXM) Trims Q1 2013 Loss, Improves Sales

Posted on 5/15/2013 @ 10:43 AM in #Stocks by QualityStocks 0 comments

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments. The company narrowed its first-quarter loss to $2.2 million from a net loss of $2.6 million for the comparable three months of 2012. Sales in the first quarter totaled $599,000, an increase compared to sales of $20,000 reported for the same period in 2012. The company attributes the increase in sales to its To Go Brands health science-based operating unit, which represents roughly 92 percent of total product sales, and sales of the Excellagen advanced wound care product, which represents 8 percent of total product sales. Research and development costs for the quarter were $762,000, as compared to $1.2 million for the prior year period. Cardium attributes the decrease to lower expenses related to the development of Excellagen, partially offset by increased costs associated with the company’s ongoing Generx ASPIRE study. Cardium also highlighted